SOLICITATION NOTICE
B -- Functional analysis of nine GRIN variants
- Notice Date
- 6/19/2014
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HG)-2014-160-DLM
- Archive Date
- 7/29/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), Undiagnosed Diseases Program (UDP) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Emory University School of Medicine, Department of Pharmacology, Rollins Lab Research Center, 1510 Clifton Road, Atlanta, Georgia 30322. Emory University will collaborate with NHGRI, NIH Undiagnosed Program to provide functional analysis of nine GRIN variants and three KCTD7 and KCTD19 variants seen in UDP patients. PROCUREMENT: This is a Follow-On Requirement: 1. Functional screening of nine (9) GRIN gene mutations; 2. Functional screening of three (3) KCTD gene mutations; and 3. Functional analysis of three (3) KCTD gene mutations BACKGROUND : The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI), National Institutes of Health Undiagnosed Disease Program (UDP) is a trans-National Institute of Health (NIH) initiative that focuses on the most puzzling medical cases referred to the NIH Clinical Center in Bethesda, Md. It was organized by the National Human Genome Research Institute (NHGRI), the NIH Office of Rare Diseases Research (ORDR) and the NIH Clinical Center. The DIR-NHGRI-Undiagnosed Diseases program (UDP) protocol 76-HG-0238, Clinical Trial Number: NCT00369421 is connected to this testing. Under this observational protocol study, the Researchers in the Protocol study have identified patients exhibiting variants GRIN and KCTD7 genes that are linked to UDP patient disease. In order to determine the pathogenic nature of these mutations, specialized patch clamp analysis will be performed using specified mutations on Xenopus laevis oocytes and cultured cells and compared to the respective wild type ion channels. UDP has continued critical need to collaborate with Emory University School of Medicine, Department of Pharmacology expertise in patch clamp analysis of mutation ion channels on 9 variants of GRIN genes and 3 variants of KCTD7 genes viewed in UDP patients in order to determine the mechanism that produces neurological disease. FDA-approved NMDAR antagonists will be evaluated to assess their ability to modify the mutant GRIN genes with gain-of-function to explore the possibility of personalized therapy for affected UDP patients. PERIOD OF PERFORMANCE : 12-Months CONTRACTOR'S REQUIREMENT : The contractor shall provide the following to the UDP laboratory : 1. Functional screen of nine GRIN gene mutations: a. Introduce UDP patient mutations (GluN2A-V452M, GluN2A-V500G, GluN2A-V967L, GluN2A-E1055Q, GluN2A-R1285K, GluN2C-E376Q, GluN2D-Y705S, GluN3A-F1029L, and GluN3B-R598C) into cDNA encoding human NMDA receptors. b. Synthesize cRNA. c. Inject mutant and wild-type NMDA receptors in to Xenopus laevis oocytes. d. Perform two-electrode voltage-clamp recordings on whole cells to determine the pharmacological and functional properties of the mutant receptors. 2. Functional screen three KCTD mutations seen in UDP patients: a. Establish GFP-fused constructs from the wild-type KCTD7 and KCTD19 constructs that the UDP provides. b. Transfect mouse-cultured neurons with wild-type KCTD7 and KCTD19 and evaluate the activation or inactivation of the potassium channel current via pharmacological isolation. c. Establish KCTD7-L27H, KCTD7-D229Y and KCTD19-S140T mutations and characterize any changes in the potassium channel functions of the mutant proteins. REGULATORY AUTHORITY: This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology, with a business size standard of 500. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-74 (May 30, 2014). This requirement is under the SAT of $150,000.00. This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by July 14, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-160-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HG)-2014-160-DLM/listing.html)
- Place of Performance
- Address: Contractor's Location, United States
- Record
- SN03400784-W 20140621/140619235135-e7188316f0b1b983c559c9124b06bef7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |